Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 407Thoracic 7Lymphoid 3Gastrointestinal 2Breast 2Sarcoma 1Gynecologic 1

Conditions

Colorectal Neoplasms 4588Pancreatic Neoplasms 2837Carcinoma, Hepatocellular 2473Stomach Neoplasms 2325Colonic Neoplasms 1790Rectal Neoplasms 1714Esophageal Neoplasms 1373Liver Neoplasms 920Neoplasms 913Breast Neoplasms 836Neoplasm Metastasis 761Carcinoma, Non-Small-Cell Lung 702Cholangiocarcinoma 581Lung Neoplasms 555Ovarian Neoplasms 533Esophageal Squamous Cell Carcinoma 510Gastrointestinal Neoplasms 494Melanoma 381Prostatic Neoplasms 371Biliary Tract Neoplasms 370Head and Neck Neoplasms 303Uterine Cervical Neoplasms 286Carcinoma, Renal Cell 282Adenocarcinoma Of Esophagus 273Sarcoma 263Squamous Cell Carcinoma of Head and Neck 262Gastrointestinal Stromal Tumors 251Endometrial Neoplasms 233Urinary Bladder Neoplasms 226Gallbladder Neoplasms 223

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Advanced Solid Tumor × Gastrointestinal × Clear all
NCT05076591 2024-10-30

IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 1 Suspended
135 enrolled
BreastGastrointestinalOther solid neoplasm

Advanced Solid Tumor

NCT05805956 2023-04-10

IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 1/2 Unknown
105 enrolled
GastrointestinalOther solid neoplasmThoracic

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡